Company HLS Therapeutics Inc Toronto S.E.

Company HLS Therapeutics Inc Toronto S.E.

AM

CA05328X1015

Equities

AM

CA05328X1015

Pharmaceuticals

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Pharmaceuticals Wholesale

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Pharmaceuticals Wholesale

Inactive Instrument

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

CAD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	80	100.0 %	85	100.0 %	+6.38%

CAD in Million	2022	Weight	2023	Weight	Delta
Canada 62.3 %	48	60.2 %	53	62.3 %	+10.03%
United States 29.3 %	25	31.8 %	25	29.3 %	-2.12%
Rest of World 8.4 %	6	7.9 %	7	8.4 %	+12.78%

Managers	Title	Age	Since
Craig Millian CEO	Chief Executive Officer	56	23-04-30
John Hanna DFI	Director of Finance/CFO	-	23-06-21
Ryan Lennox CMP	Compliance Officer	43	18-05-06
Jason Gross CTO	Chief Tech/Sci/R&D Officer	59	14-05-31
Brian Walsh PRN	Corporate Officer/Principal	-	23-05-31
Patricia Perry HRO	Human Resources Officer	48	19-06-30
David Spence AUD	Comptroller/Controller/Auditor	56	17-12-31

Members of the board	Title	Age	Since
John Welborn CHM	Chairman	46	21-06-17
Laura Brege BRD	Director/Board Member	66	19-03-20
John Hanna DFI	Director of Finance/CFO	-	23-06-21
Craig Millian CEO	Chief Executive Officer	56	23-04-30
Rodney Hill BRD	Director/Board Member	56	18-03-11
Norma Beauchamp BRD	Director/Board Member	62	20-12-31
Kyle Dempsey BRD	Director/Board Member	35	22-11-28
Christian Roy BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	31,886,247	31,730,547 ( 99.51 %)	0	99.51 %

Name	Equities	%	Valuation
Polar Asset Management Partners, Inc. 19.95 %	6,367,082	19.95 %	19 M $
Stadium Capital Management LLC 18.69 %	5,964,842	18.69 %	17 M $
Mawer Investment Management Ltd. 10.14 %	3,237,056	10.14 %	9 M $
Athyrium Capital Management LP 9.560 %	3,051,782	9.560 %	9 M $
Gilbert Godin 2.888 %	922,000	2.888 %	3 M $
John Welborn 0.3039 %	97,000	0.3039 %	284 210 $
ATB Investment Management, Inc. 0.2945 %	94,020	0.2945 %	275 479 $
Tim Hendrickson 0.2115 %	67,500	0.2115 %	197 775 $
Gregory Gubitz 0.1566 %	50,000	0.1566 %	146 500 $
Craig Millian 0.0313 %	10,000	0.0313 %	29 300 $

HLS Therapeutics, Inc.

10 Carlson Court Suite 701

M9W 6L2, Etobicoke

http://www.hlstherapeutics.com

	1st Jan change	Capi.
MCKESSON CORPORATION	+17.35%	71.39B
CARDINAL HEALTH, INC.	+2.39%	25.1B
SINOPHARM GROUP CO. LTD.	+5.38%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.19B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B
H. LUNDBECK A/S	+0.49%	4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B
EBOS GROUP LIMITED	-3.38%	3.93B
GALENICA AG	-2.61%	3.86B

Pharmaceuticals Wholesale

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Pharmaceuticals Wholesale